Results 11 to 20 of about 2,363 (167)
Frontiers in Oncology, 2023 ObjectivesTo evaluate the efficacy of Difluoromethylornithine (DFMO) chemoprevention in the high-risk population for colorectal cancer (CRC).MethodsMeta-analysis was conducted to assess the caliber of the included literature by searching five databases ...
Lifeng Yang +3 more
doaj +1 more source
High-dose DFMO alters protein translation in neuroblastoma. [PDF]
NeoplasiaABSTRACT DFMO has been studied as a cancer therapeutic at doses ranging from 500-9,000 mg/m2/day. Lower doses are favored for cancer prevention studies while higher doses, often with chemotherapy, are studied in refractory cancers. DFMO inhibits the rate-limiting enzyme in polyamine synthesis, ornithine decarboxylase (
Franson AT +6 more
europepmc +4 more sources
Frontiers in Chemistry, 2021 Targeting the polyamine biosynthetic pathway by inhibiting ornithine decarboxylase (ODC) is a powerful approach in the fight against diverse viruses, including SARS-CoV-2.
Joanna Bojarska +8 more
doaj +1 more source
A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma. [PDF]
PLoS ONE, 2015 Neuroblastoma (NB) is the most common cancer in infancy and most frequent cause of death from extracranial solid tumors in children. Ornithine decarboxylase (ODC) expression is an independent indicator of poor prognosis in NB patients.
Giselle L Saulnier Sholler +21 more
doaj +1 more source
Biomolecules, 2021 Polyamine spermidine is essential for the proliferation of eukaryotic cells. Administration of polyamine biosynthesis inhibitor α-difluoromethylornithine (DFMO) induces cytostasis that occurs in two phases; the early phase which can be reversed by ...
Mervi T. Hyvönen +4 more
doaj +1 more source
PLoS ONE, 2020 BACKGROUND:The plenteous resistance to and undesirable consequences of the existing antipiroplasmic therapies have emphasized the urgent need for new chemotherapeutics and drug targets for both prophylaxis and chemotherapy.
Gaber El-Saber Batiha +6 more
doaj +1 more source
Difluoromethylornithine is a novel inhibitor of Helicobacter pylori growth, CagA translocation, and interleukin-8 induction. [PDF]
PLoS ONE, 2011 Helicobacter pylori infects half the world's population, and carriage is lifelong without antibiotic therapy. Current regimens prescribed to prevent infection-associated diseases such as gastroduodenal ulcers and gastric cancer can be thwarted by ...
Daniel P Barry +7 more
doaj +1 more source
DFMO: Targeted risk reduction therapy for colorectal neoplasia [PDF]
Best Practice & Research Clinical Gastroenterology, 2011 Strategies to decrease intracellular polyamine levels have been studied for their efficacy in reducing colorectal cancer (CRC) risk. A successful strategy combined agents that decreased polyamine synthesis by inhibiting ornithine decarboxylase with difluoromethylornithine (DFMO), and increased cellular export of polyamines by activating the spermidine ...
Christina M, Laukaitis, Eugene W, Gerner
openaire +2 more sources
Polyamines Participate in Mycorrhizal and Root Development of Citrus (Citrus tangerine) Seedlings
Notulae Botanicae Horti Agrobotanici Cluj-Napoca, 2010 A pot experiment was conducted to study the effects of difluoromethylornithine (DFMO, an irreversible inhibitor of putrescine (Put) formation) alone or combination with Put on mycorrhizal and root development of Citrus tangerine seedlings inoculated with
Qiang-Sheng WU +3 more
doaj +1 more source
Difluoromethylornithine (DFMO) Enhances the Cytotoxicity of PARP Inhibition in Ovarian Cancer Cells
Medical Sciences, 2022 Ovarian cancer accounts for 3% of the total cancers in women, yet it is the fifth leading cause of cancer deaths among women. The BRCA1/2 germline and somatic mutations confer a deficiency of the homologous recombination (HR) repair pathway.
Olivia El Naggar +3 more
doaj +1 more source